Malaria Diagnostic Market Size Projected to Reach USD 102.83 Billion by 2035 Driven by Technological Advancements and Government Initiatives

According to Precedence Research, the global malaria diagnostic market size will rise from USD 53.16 billion in 2025 to nearly USD 102.83 billion by 2035, growing at a compound annual growth rate (CAGR) of 6.82% during the forecast period of 2026-2035.

With the malaria burden continuing to affect regions around the world, diagnostic technologies such as rapid diagnostic tests (RDTs), polymerase chain reaction (PCR) testing, and AI-driven diagnostic tools are playing an essential role in enhancing early detection and improving treatment outcomes.

Where Data Meets Strategic Clarity 📥 View Sample Pages of the Complete Report 👉 https://www.precedenceresearch.com/sample/8229

Malaria Diagnostic Market Key Growth Drivers

• Rising malaria prevalence, especially in tropical and subtropical regions, is fueling the demand for accurate diagnostic tools.

• Government initiatives aimed at malaria control and eradication are providing significant support, further stimulating the market's expansion.

🔗 What's Fueling the Next Wave of Growth? 👉 https://www.precedenceresearch.com/malaria-diagnostic-market

Malaria Diagnostic Market Opportunities

The growing demand for point-of-care testing, particularly in under-resourced areas, is expected to create significant growth opportunities for the market. Additionally, technological advancements in mobile diagnostics and AI integration are set to enhance the speed and accuracy of malaria diagnosis.

➡️ Become a valued research partner with us https://www.precedenceresearch.com/schedule-meeting

Malaria Diagnostic Market Trends

• Adoption of Rapid Diagnostic Tests (RDTs): Rapid diagnostic tests continue to gain traction globally due to their speed, affordability, and suitability for remote areas with limited access to medical facilities.

• Growth of Molecular Diagnostics: PCR and other molecular diagnostic methods are being adopted for their accuracy in detecting malaria at early stages, making them critical in both clinical and research settings.

• Artificial Intelligence (AI) in Diagnostics: AI technologies are significantly improving the accuracy and efficiency of malaria diagnostics by automating image analysis and supporting mobile-based diagnostic devices for point-of-care testing.

• Government and Global Health Initiatives: Increased investments in malaria elimination programs, including the High Burden to High Impact initiative by the WHO and national programs in countries like India, are helping to expand access to diagnostic services and accelerate market growth.

🔓 Instant Access. Zero Waiting. 📥 Buy the Premium Market Research Report Now 👉 https://www.precedenceresearch.com/checkout/8229

Malaria Diagnostic Market Regional Analysis

North America is the leading region in the malaria diagnostic market, accounting for the largest market share in 2025. The region benefits from advanced healthcare infrastructure, high investments in research and development, and a robust diagnostic industry.

The Asia Pacific region is expected to grow at the fastest CAGR during the forecast period. This is primarily due to increasing malaria prevalence in developing nations, coupled with improving healthcare infrastructure and growing government initiatives aimed at malaria control.

Note: This report is readily available for immediate delivery. We can review it with you in a meeting to ensure data reliability and quality for decision-making.

Try Before You Buy - Get the Sample Report@ https://www.precedenceresearch.com/sample/8229

Malaria Diagnostic Market Segment Analysis

🔹 Product Type Analysis

The test kits segment held the largest market share in 2025 due to the widespread use of rapid diagnostic kits in hospitals and clinics. These kits are easy to use, cost-effective, and provide quick results, making them ideal for malaria-endemic regions. Government screening programs and global health initiatives have further boosted their adoption.

The reagents segment is expected to grow at the fastest CAGR, driven by increasing use of molecular diagnostics such as PCR and laboratory-based testing. Rising demand for accurate diagnostics, expansion of lab infrastructure, and advancements in reagent quality are supporting this growth.

🔹 Technology Analysis

Rapid diagnostic tests (RDTs) dominated the market in 2025 due to their affordability, speed, and ease of use. They are particularly suitable for remote and low-resource settings, as they do not require advanced laboratory infrastructure. Support from governments and global health organizations has strengthened their adoption.

The polymerase chain reaction (PCR) segment is projected to grow at the fastest rate due to its high accuracy and ability to detect malaria at early stages. Increasing investments in molecular diagnostics and growing awareness of PCR benefits are driving its demand in clinical and research settings.

🔹 Application Analysis

The clinical diagnosis segment led the market in 2025 as it remains the primary method for detecting malaria in patients. Hospitals and diagnostic centers rely on these tools for timely and accurate diagnosis, especially in regions with high disease prevalence.

The drug efficacy studies segment is expected to grow rapidly due to the need for accurate diagnostics in evaluating treatment effectiveness. Rising investments in antimalarial drug development and clinical trials are fueling demand for precise diagnostic tools.

🔹 End User Analysis

Hospitals accounted for the largest share in 2025 due to high patient volumes and access to advanced diagnostic infrastructure. Skilled professionals and government-supported screening programs further contribute to their dominance.

Diagnostic laboratories are projected to grow at the fastest rate, driven by increasing demand for accurate testing and outsourcing of diagnostic services. Expansion of private labs and adoption of advanced technologies like PCR are key growth factors.

Malaria Diagnostic Market Top Companies and Their offerings

➢ Roche Diagnostics
↳ cobas® Malaria test: FDA‐approved molecular nucleic‐acid test on the cobas® 6800/8800 systems for screening malaria parasites in whole‐blood donations. It detects Plasmodium RNA/DNA and is positioned as a highly sensitive and specific blood‐donor screening tool in transfusion‐safety workflows.
↳ Strategy is centered on lab‐based, high‐throughput molecular screening rather than field‐oriented RDTs.

➢ Abbott Laboratories
Abbott Malaria PF/Pan Rapid Test (lateral‐flow RDT): Differentiates P. falciparum‐specific and pan‐malarial (non‐falciparum) infections from whole blood in minutes; used in clinics, hospitals, and field programs.
↳ Abbott m‐PIMATM Malaria Test (portable RDT): A small‐footprint, near‐POC device launched for rapid malaria detection in remote‐area or resource‐limited settings, enabling point‐of‐care screening.
↳ Abbott also markets branded malaria antigen tests such as Alere BinaxNOWTM Malaria (now under Abbott) for differential diagnosis of P. falciparum vs. pan‐malarial infections.

➢ Siemens Healthineers
↳ CLINITEST® Malaria Card (RDT): Lateral‐flow rapid diagnostic card for detection of malaria antigens; designed for rapid, on‐site diagnosis in clinical or low‐resource settings.
↳ Portfolio is built around mainstream RDT platforms and sample‐handling systems that can be integrated into smaller‐scale labs or outreach programs.

➢ Cepheid
↳ Cepheid does not currently market a dedicated malaria‐specific Xpert cartridge in its core portfolio; its focus remains on TB, SARS‐CoV‐2, and other ID‐NAAT panels.
↳ Its GeneXpert platform is technically capable of multiplex malaria‐NAAT assays (research‐stage or custom panels), but these are not positioned as commercial malaria‐diagnostic products in the same way as their TB/Xpert panels.

➢ Hologic
↳ Hologic does not appear to have a labeled malaria‐specific test or RDT in its current reproductive‐health and molecular‐ID portfolio; its core diagnostics are centered on gynecological oncology, STIs, and blood‐bank screening (e.g., NAT for HIV/HBV/HCV).
↳ Where Hologic participates in malaria‐related workflows, it is typically via general blood‐bank NAT or sample‐preparation platforms, not malaria‐antigen or species‐specific assays.

➢ Thermo Fisher Scientific
↳ Provides malaria RDTs and related IVD reagents under its broader infectious‐disease and microbiology portfolio, often through acquisitions or OEM partnerships; these are positioned as reliable, field‐usable lateral‐flow tests for malaria screening.
↳ Also supplies molecular components (PCR reagents, extraction kits, qPCR instruments) used in research‐ or surveillance‐grade malaria NAAT assays, though not as a branded portfolio‐level malaria test line like cobas or VYOO.

➢ Dako (Agilent Technologies)
↳ Dako's focus is on anatomical pathology and immuno‐based cancer diagnostics, and there is no widely recognized malaria‐specific IVD product explicitly branded under Dako in the malaria‐diagnostic market.
↳ Dako antibodies and reagents may be used research‐only in malaria immunohistochemistry or pLDH‐based assays, but these are not marketed as clinical malaria‐diagnostic kits.

➢ Bio‐Rad Laboratories
↳ OptiMAL‐IT (immuno‐chromatographic RDT): A reference‐grade rapid test detecting Plasmodium lactate dehydrogenase (pLDH) antigens for diagnosis of P. falciparum and P. vivax; results in about 20 minutes with high correlation to microscopy.
↳ Bio‐Rad markets OptiMAL as a field‐usable, pLDH‐based platform for malaria‐endemic countries, with emphasis on differentiating viable parasite infection from persistent HRP‐2 in treatment‐monitoring applications.

Latest Industry Developments

🔸 ISGlobal unveiled a mobile phone-based rapid malaria diagnostic test in January 2026, offering a significant leap in malaria detection, particularly for severe cases.

🔸 In June 2025, Codix Bio Ltd announced the launch of malaria rapid diagnostic test kits in partnership with SD Biosensor, aiming to expand malaria diagnostics across Africa.

🔸 In October 2025, Abbott partnered with global health organizations to expand access to rapid malaria diagnostic tests and further support malaria elimination programs.

Thank you for reading. You can also get individual chapter-wise sections or region-wise report versions, such as North America, Europe, or Asia Pacific.

📥 Instant Report Delivery Available | 💳 Buy Now 👉 https://www.precedenceresearch.com/checkout/8229

Segments Covered in the Report

🔸 By Product Type

Test Kits
Reagents
Instruments

🔸 By Technology

Rapid Diagnostic Tests
Microscopy
Polymerase Chain Reaction
Serology Tests
Loop-Mediated Isothermal Amplification

🔸 By Application

Clinical Diagnosis
Epidemiological Studies
Drug Efficacy Studies

🔸 By End User

Hospitals
Diagnostic Laboratories
Research Institutes
Home Care Settings

🔸 By Region

North America
Latin America
Europe
Asia-pacific
Middle and East Africa

Connect With Us

📞 USA: +1 804 441 9344
📞 APAC: +61 485 981 310 or +91 87933 22019 | +6531051271
📞 Europe: +44 7383 092 044
📩 Email: sales@precedenceresearch.com

Precedence Research is a worldwide market research and consulting organization. We give an unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.

🌐 Web: https://www.precedenceresearch.com

Our Trusted Data Partners:
🔹https://www.towardshealthcare.com
🔹https://www.towardspackaging.com
🔹https://www.towardschemandmaterials.com
🔹https://www.towardsfnb.com
🔹https://www.marketstatsinsight.com

Get Recent News:
https://www.precedenceresearch.com/news

For the Latest Update, Follow Us:
🔹https://www.linkedin.com/company/precedence-research
🔹https://x.com/Precedence_R
🔹https://www.facebook.com/precedenceresearch
🔹https://precedence-research.medium.com/

This release was published on openPR.